A haploid, asexual yeast and the second most common cause of invasive candidiasis after Candida albicans. Recently reclassified into the genus Nakaseomyces (as N. glabratus), though the name C. glabrata remains in widespread clinical use. Unlike C. albicans, C. glabrata does not form true hyphae and is more closely related to Saccharomyces cerevisiae than to other Candida species. Its clinical significance has risen sharply due to intrinsic resistance to fluconazole and increasing prevalence in nosocomial infections — features that make its iron dependency a particularly attractive therapeutic target.
Metal Dependencies
Iron: The Central Vulnerability
Iron is essential for C. glabrata mitochondrial function, iron-sulfur cluster assembly, and heme biosynthesis. Selective iron chelation by NR-6226C (a collismycin A analog derived from Streptomyces) potently inhibits both wild-type and drug-resistant C. glabrata with a favorable therapeutic window: EC50 of approximately 3 uM against Candida versus 37-29 uM against human cell lines (corrales 2024 iron chelating antifungal collismycin candida, in-vitro).
Transcriptomic analysis of C. glabrata treated with NR-6226C revealed an iron starvation response: 224 genes upregulated and 220 downregulated within one hour. Upregulated genes included TRR1 (thioredoxin), HMX1 (heme oxygenase), and iron import genes. Critically, iron-sulfur cluster enzyme genes were downregulated — SDH2 (succinate dehydrogenase), ACO1/2 (aconitase), and ISA1 (Fe-S assembly) — indicating severe mitochondrial iron depletion.
Copper and Zinc: Mis-metallation Compensation
A remarkable finding: copper and zinc ions ameliorate iron chelation effects on C. glabrata despite not being bound by the chelating compound (corrales 2024 iron chelating antifungal collismycin candida, in-vitro). The proposed mechanism is mis metallation — Cu2+ and Zn2+ bind to iron-dependent proteins, triggering a compensatory iron uptake response that partially overcomes chelation. This provides direct evidence that metal competition at protein binding sites has functional consequences for fungal survival.
Key Enzymes and Virulence Factors
| System | Metal | Function |
|---|---|---|
| Aft1 transcription factor | Iron sensor | Master regulator of iron starvation response |
| Iron-sulfur cluster enzymes (SDH2, ACO1/2) | Iron | Mitochondrial respiration and TCA cycle |
| HMX1 (heme oxygenase) | Iron | Heme degradation for iron recycling |
| TRR1 (thioredoxin) | — | Oxidative stress defense under iron starvation |
| ISA1 (Fe-S assembly) | Iron | Iron-sulfur cluster biogenesis |
Ecological Role
Immune Evasion Through Metabolite Sensing
Like C. albicans, C. glabrata modulates its visibility to the immune system based on the metabolic environment. Lactate triggers beta-glucan masking (hiding from immune detection), while short-chain fatty acids (butyrate, acetate) cause unmasking (alves 2020 candida adapting survive host constraints, expert-opinion). This means the metabolic balance of the gut environment directly determines whether C. glabrata is visible to immune surveillance — a dysbiotic, lactate-rich, butyrate-poor environment favors fungal stealth.
In the Mycobiome of Type 2 Diabetes
C. glabrata is detectable in the gut mycobiome of both healthy controls and type 2 diabetes patients (al bataineh 2023 multi omics microbiome metabolome t2d fiber, case-control, n=41). A key finding from this study: in T2DM, the mycobiome explains most of the microbiome variance (12.5%) while bacteria explain only 10.4% — a reversal of the normal pattern where bacteria dominate (64.2%). This suggests fungi including C. glabrata become primary ecological drivers in diabetic dysbiosis.
Fluconazole Synergy
NR-6226C synergizes strongly with fluconazole against C. albicans and related species, providing a potential combination therapy that may prevent azole resistance (corrales 2024 iron chelating antifungal collismycin candida, in-vitro). In a Galleria mellonella infection model, NR-6226C significantly increased survival of Candida-infected larvae.
Conditions Associated
- Candidemia — Second most common cause after C. albicans; increasing in nosocomial settings
- Vulvovaginal candidiasis — Common cause, particularly of azole-resistant recurrent infections
- Type 2 diabetes — Part of the disease-associated mycobiome; mycobiome variance dominance in T2DM
- Immunocompromised infections — Increasing prevalence in transplant recipients, ICU patients, and elderly populations
- Urinary tract infections — Growing cause of catheter-associated fungal UTIs
Key Studies
- corrales 2024 iron chelating antifungal collismycin candida (in-vitro) — Demonstrates selective iron chelation as potent antifungal strategy against C. glabrata; reveals Cu2+/Zn2+ mis-metallation compensation; documents fluconazole synergy and transcriptomic iron starvation response.
- alves 2020 candida adapting survive host constraints (expert-opinion) — Reviews lactate/butyrate masking-unmasking immune evasion and metabolic adaptation across Candida species including C. glabrata.
- al bataineh 2023 multi omics microbiome metabolome t2d fiber (case-control, n=41) — Multi-omics study documenting C. glabrata in T2DM mycobiome and the reversal of bacteria-fungi variance dominance in diabetes.
Cross-References
- candida albicans — Primary Candida pathogen; shares iron dependency and immune evasion strategies
- candida auris — Emerging drug-resistant Candida; related immune evasion mechanisms
- iron — Central metabolic dependency; iron chelation as therapeutic strategy
- mis metallation — Cu2+/Zn2+ compensation for iron chelation via protein mis-metallation
- butyrate — Triggers immune unmasking of Candida; ecological lever for anti-fungal defense
- antimicrobial resistance — Intrinsic fluconazole resistance; iron chelation as alternative strategy
- type 2 diabetes — Mycobiome-dominant variance signature in T2DM